Osborne Clarke advised Bone Therapeutics on the deal.
Bone Therapeutics, the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, received a €16 million loan financing from the European Investment Bank to support and prepare their lead asset, enhanced viscosupplement JTA-004, for future regulatory approval and commercialisation.
The loan financing will also be used to accelerate the clinical development of their scalable allogeneic cell therapy platform, ALLOB, which is currently being tested in a phase IIb study in patients with difficult-to-heal tibial fractures.
Bone Therapeutics is a leading biotech company listed on Euronext Brussels and Paris, which focuses on developing innovative products to address high unmet needs in orthopaedics and other diseases.
The team of Osborne Clarke in Belgium was led by Hadrien Chef (Picture) and David Haex and included Tonya Aelbrecht, Violette Keppenne, and Karen Calvo Vleugels.
Law Firms: Osborne Clarke;
Clients: Bone Therapeutics SA;